Method for treating inflammation

Abstract

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

1 . A method of suppressing or reducing IL-20 induced inflammation in a mammal comprising administering to the mammal an effective amount of a composition comprising an antibody, antibody fragment, or single chain antibody and a pharmaceutically acceptable carrier, wherein the antibody, antibody fragment, or single chain antibody antagonizes IL-20, and wherein the antibody, antibody fragment, or single chain antibody suppresses or reduces inflammation in inflammatory skin disease selected from the group consisting of psoriasis, eczema, atopic dermatitis, and contact dermatitis. 
     
     
         2 . The method according to  claim 1 , wherein the inflammatory disorder is a defensive response to mechanical trauma, toxins, neoplasia, abnormal recognition of host tissue as foreign, or invasion of the host by foreign material. 
     
     
         3 . The method according to  claim 1 , wherein the inflammatory disorder is an angiogenesis dependent chronic inflammatory condition. 
     
     
         4 . The method according to  claim 1 , wherein the inflammatory skin disease is a type of psoriasis selected from the group consisting of plaque type psoriasis, inverse psoriasis, eruptive psoriasis, and psoriasis with fingernail involvement. 
     
     
         5 . The method according to  claim 1 , wherein the composition is administered in combination with another therapeutic agent. 
     
     
         6 . The method according to  claim 12 , wherein the therapeutic agent is selected from the group consisting of a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, and a calcipotriol. 
     
     
         7 . A method of suppressing or reducing IL-20 induced inflammation in a mammal comprising administering to the mammal an effective amount of a composition comprising an antibody, antibody fragment, or single chain antibody and a pharmaceutically acceptable carrier, wherein the antibody, antibody fragment, or single chain antibody antagonizes IL-20, and wherein the antibody, antibody fragment, or single chain antibody suppresses or reduces inflammation in an inflammatory lung disease selected from the group consisting bronchitis, lung cancer, bacterial pneumonia, and idiopathic pulmonary fibrosis. 
     
     
         8 . The method according to  claim 7 , wherein the inflammatory disorder is a defensive response to mechanical trauma, toxins, neoplasia, abnormal recognition of host tissue as foreign, or invasion of the host by foreign material. 
     
     
         9 . The method according to  claim 7 , wherein the inflammatory disorder is an angiogenesis dependent chronic inflammatory condition. 
     
     
         10 . The method according to  claim 7 , wherein the composition is administered in combination with another therapeutic agent. 
     
     
         11 . The method according to  claim 10 , wherein the therapeutic agent is selected from the group consisting of a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, and a calcipotriol. 
     
     
         12 . A method of suppressing or reducing IL-20 induced inflammation in a mammal comprising administering to the mammal an effective amount of a composition comprising an antibody, antibody fragment, or single chain antibody and a pharmaceutically acceptable carrier, wherein the antibody, antibody fragment, or single chain antibody antagonizes IL-20, and wherein the antibody, antibody fragment, or single chain antibody suppresses or reduces inflammation in an inflammatory bowel disease selected from the group consisting of ulcerative colitis and Crohn's disease. 
     
     
         13 . The method according to  claim 12 , wherein the inflammatory disorder is a defensive response to mechanical trauma, toxins, neoplasia, abnormal recognition of host tissue as foreign, or invasion of the host by foreign material. 
     
     
         14 . The method according to  claim 12 , wherein the composition is administered in combination with another therapeutic agent. 
     
     
         15 . The method according to  claim 14 , wherein the therapeutic agent is selected from the group consisting of a lubricant, keratolytic, topical corticosteroid, topical vitamin D derivative, anthralin, systemic antimetabolite, methotrexate, psoralen-ultraviolet-light therapy (PUVA), etretinate, isotretinoin, cyclosporine, and a calcipotriol.